Jesper A. Palshof

Herlev, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 22, 2026

Title Not Found

Title Not Found

Journal: Ugeskrift for laeger

Published: August 08, 2024

Combination therapy with immune check point inhibitors and acute kidney injury.

Combination therapy with immune check point inhibitors and acute kidney injury.

Journal: Acta oncologica (Stockholm, Sweden)

Published: February 09, 2023

Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol.

Active use of electronic patient-reported outcome in kidney cancer and effect on self-reported physical function: PRORECECA study protocol.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 09, 2022

Individualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study.

Individualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study.

Journal: JMIR research protocols

Published: January 19, 2022

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.

Journal: International journal of molecular sciences

Published: June 07, 2020

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.

Journal: Cancer chemotherapy and pharmacology

Published: July 20, 2018

Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.

Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.

Journal: Acta oncologica (Stockholm, Sweden)

Published: January 31, 2018

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.

Journal: International journal of molecular sciences

Published: July 31, 2017

Risk factors for brain metastases in patients with metastatic colorectal cancer.

Risk factors for brain metastases in patients with metastatic colorectal cancer.

Journal: Acta oncologica (Stockholm, Sweden)

Published: April 28, 2017

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.

Journal: BMC cancer

Published: January 27, 2016

Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.

Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.

Journal: Scientific reports

Published: December 03, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026